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Role of Cyclooxygenase-2 on 
Intermittent Hypoxia-Induced 
Lung Tumor Malignancy in a Mouse 
Model of Sleep Apnea
Noelia Campillo1,2,3, Marta Torres3,4, Antoni Vilaseca1, Paula Naomi Nonaka1, David Gozal5, 
Jordi Roca-Ferrer3,6,7, César Picado3,6,7, Josep Maria Montserrat3,4, Ramon Farré1,3,6, 
Daniel Navajas1,2,3 & Isaac Almendros1,3,6
An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has recently 
emerged from clinical and animal studies. In animals, intermittent hypoxia (IH) mimicking OSA 
promotes tumor malignancy both directly and via host immune alterations. We hypothesized that IH 
could potentiate cancer aggressiveness through activation of the cyclooxygenase-2 (COX-2) pathway 
and the concomitant increases in prostaglandin E2 (PGE2). The contribution of the COX-2 in IH-induced 
enhanced tumor malignancy was assessed using celecoxib as a COX-2 specific inhibitor in a murine 
model of OSA bearing Lewis lung carcinoma (LLC1) tumors. Exposures to IH accelerated tumor 
progression with a tumor associated macrophages (TAMs) shift towards a pro-tumoral M2 phenotype. 
Treatment with celecoxib prevented IH-induced adverse tumor outcomes by inhibiting IH-induced 
M2 polarization of TAMs. Furthermore, TAMs isolated from IH-exposed mice treated with celecoxib 
reduced the proliferation of LLC1 naïve cells, while the opposite occurred with placebo-treated IH-
exposed mice. Finally, in vitro IH exposures of murine macrophages and LLC1 cells showed that both 
cell types increased PGE2 release in response to IH. These results suggest a crucial role for the COX-2 
signaling pathway in the IH-exacerbated malignant processes, and designate macrophages and lung 
adenocarcinoma cells, as potential sources of PGE2.
Obstructive sleep apnea (OSA) is a prevalent condition characterized by repetitive occlusions of the upper airway 
during sleep resulting in intermittent hypoxia (IH), increased respiratory efforts and sleep fragmentation1. Over 
the last several decades, epidemiological, clinical and experimental evidences have provided significant support 
to the contention that OSA, and more specifically IH, operates as an independent risk factor for cardiovascular, 
cognitive and metabolic morbidities2–4. More recently, a potential link between OSA and cancer incidence and 
mortality has also been proposed based on epidemiological and animal studies5–9.
The presence of hypoxia within the tumor microenvironment can impair anti-cancer immunity responses 
through alterations in the secretion of cytokines, chemokines and other pro-inflammatory molecules that mediate 
the cross-talk between tumor cells and immune cells in the tumor stroma10–12. In the context of OSA, recent stud-
ies indicate that IH can facilitate cancer progression mainly through alterations in the host immune response13–15. 
More specifically, IH increases the mobilization of tumor-associated macrophages (TAMs) into the tumor, and 
accelerates their transformation from an anti-tumoral phenotype (M1) to a tumor-promoting phenotype (M2). 
In addition to TAMs, the recruitment of other immunosuppresive populations such as myeloid-derived suppres-
sor cells (MDSCs) or regulatory T lymphocytes (Tregs) from surrounding tissues is also enhanced by IH13–15. 
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Taken together, the IH-induced changes on the tumoral immune response would be anticipated to lead to a more 
tumor-permissive microenvironment, thus facilitating processes such as tumor growth, invasion, or dissemina-
tion, as previously reported8,9,13.
The cyclooxygenase-2 (COX-2) downstream metabolite prostaglandin E2 (PGE2) has been proposed to play a 
critical role in the interplay between tumor cells and stromal cells16,17. PGE2 can promote tumor cell proliferation, 
migration and invasion either directly, or indirectly through induction of a tumor-permissive microenvironment 
characterized by impaired immunosurveillance and increased angiogenesis16–18. Indeed, several reports have 
shown that COX-2 is up-regulated in different types of tumors, including colorectal, breast or lung carcinomas, 
and such altered expression of COX-2 is directly correlated with poor prognosis17,19. Hence, targeting COX-2 
activity through nonsteroidal anti-inflammatory drugs (NSAIDs) has been proposed as a potentially promising 
strategy in the prevention and treatment of cancer20. In this context, NSAIDs have been widely employed over the 
last decades in pre-clinical and clinical trials as COX inhibitors, facilitating anti-tumoral host immune responses 
(mainly through the reduction of the M2-like polarization of TAMs and the infiltration of regulatory cells), and 
decreasing the incidence and mortality in several types of cancer21,22.
Even though COX-2 expression is stimulated by oncogenes, tumor promoters, growth factors and 
cytokines23,24, several reports point to an important role of microenvironmental factors, such as tumor hypoxia, 
in the up-regulation of COX-2 expression and the resultant tumor progression25,26. Previous in vitro studies have 
shown that COX-2 is up-regulated in endothelial and tumor cells in response to IH to levels that exceed even 
those observed in cells exposed to continuous hypoxia27. However, the IH cyclical pattern applied in the in vitro 
study clearly differs from the IH patterns that are characteristic of OSA, since the former occurs as a consequence 
of the irregular blood flow caused by aberrant non-periodic occlusions in vessels during tumor growth (last-
ing from many minutes to hours), while the latter is associated with recurrent apneas (lasting only seconds to 
minutes). Rodent studies focused on OSA have also reported a causal role of COX-2 in the microglial-specific 
neuroinflammation and the adverse neurocognitive consequences in response to IH28,29. Therefore, we used cel-
ecoxib (Ce), a well-characterized and specific COX-2 inhibitor, to investigate whether the COX-2/PGE2 signaling 
pathway participates in the IH-induced exacerbation of malignant processes using a mouse model of OSA bear-
ing Lewis lung carcinoma (LLC1) tumors. Furthermore, we also assessed which cell type, namely macrophages or 
tumor cells, provides the major source of PGE2 in response to IH using a well-established in vitro model.
Methods
Cells and reagents. Mouse Lewis lung carcinoma cells (LLC1) and mouse macrophages (RAW 
264.7) (American Type Culture Collection, Manassas, VA) were routinely grown as described in the online 
Supplementary Material. Celecoxib (Ce) preparation and administration, as well as antibodies for fluores-
cence-activated cell sorting (FACS) are also detailed in this section.
Animals, in vivo IH exposure and drug treatment. Forty C57BL/6 J 10-week old male mice, obtained 
from Charles River Laboratories (Saint Germain sur L’Arbresle, France), were maintained in a 12-h light/dark 
cycle and fed with a regular diet chow and tap water ad libitum. All experimental procedures were approved by 
the Ethical Committee for Animal Research of the University of Barcelona (67/15), following relevant guidelines 
on the care and use of animals and were authorized by the Generalitat de Catalunya Government (8473).
Mice were randomly exposed to either IH (n = 20) or normoxia (N) (n = 20) using an experimental setting 
previously described8. The IH pattern consisted of cycles of 40 seconds of 21% FiO2 followed by 20 seconds 5% 
FiO2 for 6 h/day, 6 days/week. This pattern reproduces the oscillations in the arterial oxygen saturation (95.4% 
to 62.3%) observed in moderate to severe OSA patients30. The control group was identically instrumented, but 
subjected to N (21% FiO2). After one week of exposures to N or IH, ten mice from each group were treated 
daily with 75 mg/kg body weight of Ce or vehicle (14% DMSO in sesame oil) via oral gavage (Fine Science Tools 
GmbH, Heidelberg, Germany), and the drugs were administered one hour prior to initiation of IH or N expo-
sures. Therefore, four groups were performed: animals subjected to N or IH and treated with vehicle or Ce (N, 
N+ Ce, IH, IH+ Ce, n = 10 each) (Fig. S1). The daily Ce dose employed was below the maximum tolerated for 
mice (250 mg/kg) and similar to several other studies on the effects of Ce on cancer31,32.
Lung tumor induction and assessment of tumor malignancy. Prior to the inoculation of tumor cells 
in mice, the capacity of LLC1 to respond to PGE2 (Cayman Chemicals) was examined in vitro. To that end, LLC1 
cells were seeded in triplicate on 24-well plates at a density of 65,000 cells/well and treated with 10−6 mM PGE2. 
The concentration of PGE2 chosen for this assay was similar to that measured in the plasma of different murine 
cancer models33,34. Cells were maintained for 40 h at 20% O2, 5% CO2, 100% humidity and 37⁰C. At the end-point 
of the experiments, cells were harvested, stained with trypan blue (Sigma-Aldrich, St. Louis, MO) and live cells 
were counted in a Neubauer chamber using an optical inverted microscope.
After two weeks of pre-exposures to IH or N, animals were subcutaneously injected with 105 LLC1 cells sus-
pended in 0.2 ml of 1x phosphate buffered saline (PBS) in the right flank. Once tumors became palpable, tumor 
volume was estimated as described before13. All mice were euthanized by exsanguination followed by cervical 
dislocation at day 21 post-injection. Tumors were excised, weighted and the disruption of capsule with presence 
of invasion toward the skeletal muscle was visually assessed by two blinded investigators. Samples were prepared 
for FACS, TAMs isolation and western blot (WB). Lung lobes were extracted, fixed in Histofix (Panreac) and 
paraffin-embedded. Blocks were cut into 4 μ m sections, stained with hematoxylin/eosin and blindly examined 
under light microscopy to assess metastatic potential by one of the investigators who was unaware of the treat-
ment group. Total number of LLC1 metastases, relative metastatic area and mean size of each metastasis per 
group were calculated. Histological sections were also performed in some tumor samples and examined under 
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microscopy to confirm findings regarding tumor invasion. COX-2 protein levels in the tumor were examined by 
WB (see online Supplementary Material for detailed protocol).
Assessment of Tregs, MDSCs and TAMs populations by flow cytometry. Tumors were minced and 
digested in a 1 mg/mL collagenase type IA (Gibco, Gaithersburg, MD) solution for 1 h at 37 °C. Cells were filtered 
through a 100 μ m nylon mesh cell strainer (BD Falcon, Bedford, MA) and stained with fluorophore-conjugated 
antibodies for the identification and quantitative analysis of Tregs, TAMs and MDSCs populations by FACS as 
previously described13. Labelled cells were analyzed on a FACS Canto II cytometer using FACS Diva 5.5 software 
(BD Biosciences, San Jose, CA) and analyzed by FlowJo software (Tree Star, San Carlos, CA). The subpopula-
tion of Tregs was identified by FoxP3 and CD45+ , CD3+ , CD4+ , CD8−, CD25+ cell surface markers, while 
MDSCs were recognized by CD45+ , CD11b+ and Gr-1+ markers, and TAMs as CD45+ , CD11b+ and F4/80+ . 
Polarization of TAMs towards M2 or M1 phenotype was assessed by measuring CD206 or CD86 surface mark-
ers, respectively. In addition, the M2/M1 ratio was computed from the quotient between the mean fluorescence 
intensity (MFI) values for CD206 and CD86 markers. Isotype controls were employed to establish background 
fluorescence. Cell populations were measured as cells per gram of tumor and total numbers of TAMs, Tregs and 
MDSCs recruited within the tumor.
Determination of M1/M2 TAMs phenotype by real-time polymerase chain reaction. Gene 
expression analyses of M1 (INF-γ , interferon gamma) and M2 markers (MRC1, mannose receptor C type 1; 
IL-10, interleukin 10) by real-time polymerase chain reaction (qPCR) were performed in isolated TAMs to fur-
ther assess their polarization. Firstly, TAMs were purified from digested tumors by CD11b-PE magnetic label-
ling (EasySepTMMouse CD11b Positive Selection Kit, StemCell Technologies, Vancouver, BC) following the 
manufacturer’s protocol. Then, total RNA from isolated TAMs was extracted using the RNeasy kit (Qiagen, 
Hilden, Germany) and 0.5 μ g were used to synthesize cDNA by reverse transcription polymerase chain reaction, 
according to manufacturers’ instructions. qPCR was performed using the Taqman Gene Expression Master Mix 
(ThermoFisher Scientific, Waltham, MA) in a StepOnePlus thermocycler (ThermoFisher Scientific, Waltham, 
MA). Relative gene expression normalized to eukaryotic 18 S rRNA endogenous control was calculated using 
the 2−∆∆CT method to quantify fold change in gene expression of IFN-γ , IL-10 and Mcr1 compared to baseline 
expression (N group). Taqman Gene Expression Assays were purchased from ThermoFisher Scientific. PTGS2 
(prostaglandin-endoperoxide synthase 2) relative gene expression was also assessed in TAMs from N and IH 
groups to complement data regarding COX-2 protein expression in tumors.
Co-culture of tumor associated macrophages with LLC1 cells in vitro. Isolated TAMs were 
co-cultured with LLC1 naïve cells (4:1 ratio) in full media for three days13. At the end point, cells were harvested, 
labeled with CD45-FITC and both cell types were identified (TAMs as CD45+ cells and LLC1 as CD45− cells) 
and counted by FACS to determine LLC1 proliferation.
Assessment of PTGS2 gene expression and PGE2 production by LLC1 and RAW 264.7 cells 
exposed to IH in vitro. LCC1 and RAW 264.7 cell exposures to N (20% O2) or IH (30 s 1% O2–30 s 20% O2) 
were performed using a custom-made system adapted from a chip previously described35. The chip employed 
herein is composed by two PDMS layers designated as gas and culture chambers containing six PDMS wells of 
12 mm diameter each. Both chambers are separated by a 20 μ m thick PDMS membrane (Fig. S2a,b). Wells of the 
gas chamber are connected in series allowing circulation of gases from a gas source providing a constant mixture 
of gases (N) or oscillations in gas composition (IH) to the six independent cell cultures adhered on top of the 
membrane (culture chamber). Oxygen measurements performed on top of membrane (at the cell culture level) 
using a fiber-optic oxygen sensor (FireSting O2, Pyro Science, Aachen, Germany) showed that, in agreement 
with our previous study, the system displays a fast equilibration time (~6 s) due to fast oxygen diffusion through 
the thin membrane (Fig. S2c). Therefore, oxygen desaturation patterns experienced by OSA patients can be rep-
licated at the cell culture level or in living animal tissues using the in vitro and in vivo models described herein, 
respectively.
Prior to experiments, the viability of LLC1 and RAW 264.7 cells at different concentrations of Ce was tested 
such as to select the optimal concentration and avoid toxicity-induced cell death (see Supplementary Fig. S3). 
LLC1 and RAW 264.7 single cultures treated with Ce (10 μ M) or vehicle (0.05% DMSO) were exposed to either 
IH (30 s 1% O2–30 s 20% O2) or N (20% O2) for 24 h (Fig. S2d). Then, supernatants were collected, centrifuged at 
300 g for 5 min to discard possible cells in suspension and total levels of PGE2 (pg) in cell media supernatants were 
determined using mouse PGE2 ELISA kit (Cayman Chemical, Tallinn, Estonia), according to the manufacturer’s 
protocol. RAW264.7 and LLC1 cells were harvested and PTGS2 relative gene expression was assessed as described 
above for the in vivo study.
Statistical analysis. Data are reported as mean ± standard error (SE). Shapiro-Wilk tests were per-
formed to ensure normal distribution of samples prior to analysis. Data from N, N+ Ce, IH, IH+ Ce groups 
were compared using two-way analysis of variance (ANOVA). Gas and drug exposures constituted the variables. 
Student-Newman-Keuls post hoc test was used for multiple comparisons. T-test analyses were used to compare 
LLC1 in vitro proliferation in presence or absence of PGE2, COX-2 protein levels in tumors and PTGS2 gene 
expression in TAMs from N and IH groups. Differences were considered significant for p < 0.05. Statistical anal-
yses were performed with SigmaPlot (Systat Software, San Jose, CA).
Results
Celecoxib inhibits IH-induced tumor malignancy changes. IH exposures promoted acceler-
ated tumor growth from tumor weight and tumor volume measurements (2.07 g ± 0.28 and 1.57 cm3 ± 0.18, 
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respectively) when compared to normoxic mice (0.95 g ± 0.15, p < 0.001; 0.90 cm3 ± 0.19 p = 0.005) (Fig. 1a,b). 
Similarly, the number of mice presenting evidence of local tumor invasion in surrounding tissues was higher 
in mice exposed to IH (Fig. 1c). No statistically significant differences emerged in the total number of LLC1 
metastases, relative metastatic area, and mean size of metastases among the different groups (Fig. 1d). While the 
number of metastases slightly increased in mice exposed to N, the mean size of the metastases was lower than the 
observed in the IH groups. Nevertheless, the large variability among samples within the same treatment group 
hindered the statistical analyses. Tumors from IH-exposed mice presented a trend to an increased COX-2 protein 
expression in comparison to N (p = 0.284) (Fig. 1e). Similarly, isolated TAMs also exhibited a trend to increased 
expression of the PTGS2 gene (p = 0.106) (Fig. 1f). Daily administration of Ce markedly decreased IH-induced 
tumor growth (tumor weight = 0.42 g ± 0.12; tumor volume = 0.38 cm3 ± 0.13, p < 0.001) (Fig. 1a,b). Application 
of PGE2 to LLC1 cells in vitro elicited a 2-fold increase in proliferation (p = 0.017), confirming that this tumor 
model functionally responds to PGE2 (Fig. 1g).
Celecoxib suppresses the IH-induced alterations in the host immune response. In absence of 
Ce treatment, a 2-fold increase (p = 0.014) in TAMs population and 2.5-fold increases in MDSCs (p = 0.014) and 
Tregs (p = 0.006) counts emerged in tumors from mice exposed to IH when compared to the N group (Fig. 2a). 
Conversely, in IH-exposed animals receiving Ce, TAMs, Tregs and MDSCs counts were restored to N basal levels. 
When normalizing for tumor weight (Fig. 2b), the number of TAMs, MDSCs and Tregs remained similar among 
the different conditions. See Fig. S4 for representative flow cytometry dot plots of gated populations.
Most importantly, IH exposures induced a polarity shift in TAMs from an anti-tumoral phenotype (M1) 
towards a tumor-promoting phenotype (M2), as reflected by a ~2-fold increase in M2/M1 ratios when compared 
to mice exposed to N (p < 0.001) (Fig. 3a). Accordingly, qPCR analyses carried out on isolated TAMs revealed 
that IH treatment downregulated the expression of the M1 marker INF-γ (p = 0.021) while the expression of 
the M2 markers MCR1 (p = 0.008) and IL-10 (p = 0.083) was up-regulated, in comparison to N (Fig. 3b). On 
the other hand, the M2/M1 ratios in Ce-treated mice exposed to IH as well as the expression of genes associated 
with M1 and M2 phenotypes were restored to levels similar to those found among tumors in normoxic mice. No 
changes in TAMs polarization were observed between N and N+ Ce groups.
Co-culture of naïve LLC1 with TAMs from tumors of IH-exposed mice induced increased proliferation rela-
tive to N-exposed TAMs (Fig. 3c, p = 0.009). However, when LLC1 cells were co-cultured with TAMs from IH+ 
Ce-exposed mice, cell numbers were significantly decreased to levels slightly below those of LLC1 co-cultured 
with N TAMs (p = 0.003).
Celecoxib inhibits the increased PGE2 production by LLC1 and RAW 264.7 cells in response to 
IH in vitro. RAW 264.7 macrophages and LLC1 cells exposed to IH for 24 h exhibited ~4.5-fold and ~1.5-fold 
increases in PGE2 production, respectively (Fig. 4a, n = 6 p < 0.001; Fig. 4b, n = 5, p = 0.014), when compared to 
normoxic conditions. Similarly, IH induced an up-regulation of PTGS2 expression in macrophages (p = 0.003), 
while no changes were observed in the PTGS2 gene expression in tumor cells (Fig. 4c,d). The addition of 10 μ M 
Ce to the cell media significantly reduced PGE2 secretion to levels observed under normoxia (RAW 264.7) or 
even below (LLC1 cells) (p < 0.001), while PTGS2 gene expression did not change in response to Ce treatment.
Discussion
In this study, we found that the IH-induced enhancements of tumor malignancy are mediated, at least in part by 
the COX-2/PGE2 signaling pathway. The application of the COX-2 specific inhibitor Ce suppressed IH-induced 
alterations in the host immune response within the tumor microenvironment, leading to a marked reduction in 
tumor growth. Furthermore, LLC1 cells increased their proliferative rates in response to exogenous PGE2 at con-
centrations previously measured in several types of cancer33,34. In vitro exposure of macrophages and LLC1 cells 
to IH resulted in the activation of the COX-2/PGE2 pathway, suggesting that these cells are likely sources of PGE2 
in the tumor microenvironment and also can further increase in response to IH.
Recent clinical and translational studies have suggested a link between OSA and increased cancer incidence, 
aggressiveness and mortality5–9. Animal studies have further revealed that IH exposures that mimic OSA-induced 
oxygenation patterns during sleep lead to accelerated tumor growth, invasiveness and metastasis in certain types 
of tumors such as lung carcinoma13 and melanoma9. In the present study, LLC1 tumors had similar responses 
to IH as those reported in previous studies with other types of cancer cells8,9,13. Concretely, IH led to increased 
tumor growth and invasiveness in LLC1 tumors. In contrast to previous findings, no changes in tumor metastases 
were observed, a finding that may be explained by the highly aggressive metastatic behavior of these cells even 
in control conditions32. PTGS2 gene and COX-2 protein expression showed a trend toward increases in purified 
TAMs and in tumors isolated from IH-exposed mice in comparison to normoxia, respectively. Given that the 
biological material available to perform WB and qPCR analyses was limited owing to the reduced size of tumors 
(especially in Ce groups) and that samples were mostly used to perform FACS analyses and TAMs co-cultures 
with LLC1, it becomes apparent that larger sample sizes would be desirable to draw a more definitive conclusion. 
Regarding the immune alterations promoted by IH, our results are closely concordant with previous data on other 
tumors13,14. FACS analysis revealed alterations in TAMs polarity from the classically activated anti-tumoral M1 
phenotype towards an alternatively activated pro-tumoral M2 phenotype. Accordingly, qPCR analyses further 
confirmed the enhanced expression of MRC1 and IL-10 genes (M2 markers) and the decreased expression of 
IFN-γ (M1 marker) in TAMs isolated from IH-exposed mice. In fact, the polarity switch of TAMs is currently 
considered a key step in the acceleration of cancer aggressiveness, and has been directly associated with a poor 
prognosis in several types of tumors36,37. Despite the fact that IH-exposed tumors had increased TAMs, MDSCs 
and Tregs counts, the number of cells per gram of tumor remained similar among groups, suggesting that the 
increased tumor aggressiveness observed in animals treated with IH is most likely explained by a change in 
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Figure 1. Tumor growth and invasion in celecoxib (Ce) or vehicle-treated mice exposed to normoxia (N) or 
intermittent hypoxia (IH). (a) Periodic tumor volume measurements revealed an accelerated tumor growth in 
IH-treated mice compared to N, which was inhibited by Ce administration. (b) Weight average of tumors from 
mice exposed to IH experienced ~2-fold increase respect to N. Under IH conditions, daily administration of 
Ce promoted a markedly reduction in tumor weight. (c) Representative histological sections of the tumor and 
the adjacent muscle presenting non-invasion (left) or invasion (right). LLC1 cells are predominantly stained by 
hematoxylin (dark blue, yellow arrows) whereas myocytes are more intensely stained with eosin (pink, white 
arrows). Scale bar = 100 μ m. The number of mice presenting invasion was higher in IH vs N exposed mice.  
(d) Number of lung metastases, mean size, and relative metastatic area do not exhibit significant variations among 
the different treatments due to a high intra-group variability. Representative image of a metastasis (yellow arrow) 
in the lung parenchyma. Scale bar = 100 μ m. Tumors (e) and purified TAMs (f) from IH-exposed mice showed a 
trend to an increased COX-2 protein and PTGS2 gene relative expression, respectively. (g) LLC1 proliferation in 
response to exogenous PGE2 in vitro. Data are presented as mean ± SE.
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TAMs phenotype rather than ascribable to an increased infiltration of other immunosuppressive populations. 
Other studies observed an accumulation of MDSCs and Tregs which was associated with increased malignant 
properties, since both populations impair tumor immunosurveillance by limiting the infiltration and functions 
of cytotoxic populations38, while also promoting the M2-like polarization of TAMs39.
There is increasing evidence suggesting that biochemical signals participating in the cross-talk between 
tumor cells and tumor stromal cells are essential for cancer escape (i.e. transcription factors, growth factors and 
some cytokines)40. In addition, biophysical cues of the tumor microenvironment (i.e. hypoxia41 or extracellular 
matrix components which can modulate its stiffness42) have also been implicated. PGE2, a downstream product 
of COX-2 enzymatic activity, has been identified as a major orchestrator, coordinating the pro-angiogenic and 
immunosuppressive programs that facilitate tumor growth and contribute to cancer progression16,18. Regarding 
immunosuppression, a large body of evidence indicates that PGE2 plays an important role in the initiation and 
maintenance of M2 polarized TAMs, as well in promoting the suppression of M1 polarity22,43. In addition, PGE2 
downregulates anti-tumoral Th1 responses while promoting pro-tumoral Th2 responses of T helper cells44, lim-
its the proliferation and functionality of cytotoxic T-lymphocytes and natural killer (NK) cells16,45, induces the 
recruitment of Tregs and MDSCs populations16, and inhibits the differentiation of dendritic cells46. Moreover, 
PGE2 also increases the proliferation, survival, migration and invasion of tumor cells through its binding to their 
Figure 2. Tumor associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and 
regulatory T cell lymphocytes (Tregs) within the tumor. (a) Application of IH resulted in an enhanced tumor 
weight and hence increased total number of TAMs, MDSCs and Tregs populations within the tumor, while Ce 
administration prevented tumor growth and therefore reduced cell numbers. b) No significant differences in cell 
population density (cells/g of tumor) of TAMs, MDSCs and Tregs were observed amongst different groups. Data 
are presented as mean ± SE.
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Figure 3. Polarization of tumor-associated macrophages (TAMs) and their effects on LLC1 cell 
proliferation. (a) Assessment of CD206 (M2 phenotype marker, upper) and CD86 (M1 phenotype marker, 
lower) in TAMs by FACS as well as representative mean fluorescence intensity (MFI) histograms of each marker 
in N, N+ Ce, IH and IH+ Ce samples. Up-regulation of M2 marker was observed in TAMs from mice that 
underwent IH treatment, whereas Ce resulted effective avoiding M2-like polarization. M2/M1 ratio calculated 
from the quotient between CD206 and CD86 MFIs increased consistently in IH-exposed animals, and was 
prevented in IH-treated mice that received Ce (center). (c) Proliferation of LLC1 cells co-cultured with TAMs 
isolated from mice. LLC1 cells increased their proliferation when co-cultured with TAMs obtained from IH-
exposed mice, whereas IH+ Ce TAMs significantly reduced LLC1 cell proliferation respect to the IH-treated 
group. Representative dot plot depicting the gating performed to identify CD45+ , CD11b+ (TAMs) and 
CD45− , CD11b− (LLC1) populations during FACS analysis. Data are presented as mean ± SE, MFI = Mean 
fluorescence intensity (arbitrary units).
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specific receptors47. In fact, high levels of PGE2 in the tumor resulting from the aberrant activation of COX-2 
are commonly considered as indicators of a poorer cancer prognosis in different types of malignancies such as 
melanoma, breast, colon, lung, or gastric cancer17. In this study, LLC1 cells exposed in vitro to PGE2 augmented 
their proliferative rate revealing their susceptibility to respond to this inflammatory mediator likely through its 
binding to the EP4 receptor48 (Fig. 1g). Although COX-2 up-regulation in cancer cells has been classically linked 
to the activation of oncogenes or transcription factors, it has been also detected in tumor cells and other cells of 
tumor stroma in response to hypoxia, via stabilization of hypoxia inducible factor 1 (HIF-1) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κ B)25,26,49. In fact, hypoxic regions of the tumor positively 
correlate with increased COX-2 expression, accumulation of M2-like polarized macrophages and other immu-
nosuppressive cells41.
In the context of IH, a previous study showed the potential involvement of COX-2 in the transcriptomic adap-
tation of endothelial and tumor cells to low frequency cyclic hypoxia27. Similarly, studies in the field of OSA, also 
reported the participation of COX-2 in the pathogenesis of OSA-related morbidities28. Thus, the link between 
COX-2 and IH is not only biologically plausible, but further appears to underlie components of the enhanced 
aggressive biological properties of cancer in the context of OSA. To characterize the potential implications of 
COX-2/PGE2 signaling pathway in the IH-enhanced tumor growth and aggressiveness in the mouse model of 
OSA bearing LLC1 tumors, we employed Ce, a specific inhibitor of COX-2. Experimental studies and clinical trials 
have been carried out over the last decades to assess the potential therapeutic role of Ce and other COX-2 inhibi-
tors in the prevention and treatment of different types of cancer20,21. Although most clinical trials point to a better 
prognosis in patients receiving Ce treatment in addition to chemo-, radio- or chemoradiotherapy, there is still a 
lack of consensus and certainly some degree of controversy about the therapeutic role of this compound, probably 
due to the presence of multiple other confounding factors affecting cancer outcomes50,51. Notwithstanding, the 
effectiveness of Ce in delaying tumor growth and improving cancer prognosis has been shown in several types of 
cancer both in vivo and in vitro, when experimental conditions were tightly controlled22,32. In the present study, the 
effect of Ce on tumor growth was evident in IH-exposed animals, and induced 5-fold reductions in tumor weight 
and volume. In addition, Ce reduced the number of animals presenting tumor invasion to adjacent muscle. These 
improvements in cancer prognosis could be partially explained by the recovery of the anti-tumoral responses of 
the immune system as reflected by increases in M1 polarized TAMs and reductions in the M2-like polarization 
of TAMs through the specific inhibition of COX-2 by Ce, as determined by FACS, qPCR and ELISA analyses. 
Similar findings were previously observed in murine models of cancer that were unrelated to OSA or IH22,52. 
Figure 4. Alterations in the COX-2/PGE2 signaling pathway in by RAW 264.7 and LLC1 cells exposed to IH 
and/or Ce treatment in vitro. PGE2 secretion by RAW 264.7 macrophages (a) and LLC1 cells (b) exposed to IH 
increased significantly in comparison to N, while Ce administration resulted in a reduction of PGE2 production 
in both cell types near to N levels (RAW 264.7 cells) or even below (LLC1 cells). PTGS2 relative gene expression 
was up-regulated in RAW264.7 cells in response to IH (c) while no changes were detected in the case of PTGS2 
by LLC1 cells between different treatments (d). Data are presented as mean ± SE.
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Some studies have also documented an increase in the infiltration of cytotoxic T-lymphocytes and NK cells53. 
Although we did not assess the effects of IH and/or Ce on the recovery of such immune populations, we would 
anticipate similar findings based on the reduction of PGE2 production by Ce.
The in vitro experiments carried out with isolated TAMs from tumors confirmed that the phenotypic changes 
have implications in LLC1 proliferation in co-culture. Similar to our previous findings13, LLC1 naïve cells 
co-cultured with TAMs from mice exposed to IH showed increased proliferation over those co-cultured with 
N-exposed TAMs. When co-cultured with TAMs from IH-exposed animals treated with Ce, LLC1 cells signif-
icantly reduced their proliferation. Moreover, LLC1 single cultures showed higher proliferative capacity when 
exogenous PGE2 at a concentration similar to that found in plasma from different mouse models of cancers33,34 
was added to the media. These findings confirm that PGE2 is able to directly induce tumor cell growth in our 
model, most likely through binding to specific receptors in LLC1 cells.
Macrophages and tumor cells (RAW 264.7 and LLC1 cell lines, respectively) were single cultured and exposed 
to IH in vitro in order to identify which cells is the major source of PGE2 in the tumor in response to IH. qPCR 
and ELISA analyses revealed that IH induced significant increases in PTGS2 gene expression and PGE2 pro-
duction by macrophages. In tumor cells, PGE2 production was also increased in response to IH; however, no 
changes on PTGS2 gene expression were detected. This finding could be explained by the increased expression 
of PTGS2 on tumor cells even in basal conditions23,24, with IH most likely being associated with modulation of 
expression at the protein level. Addition of Ce to the media inhibited PGE2 production, supporting the efficiency 
of this drug in delaying tumor malignancy by reducing PGE2 secretion by TAMs and cancer cells and also their 
positive-feedback, hence supporting the findings in vivo43. Taken together, these results suggest that despite the 
fact that macrophages are more prone to exhibit alterations in the COX-2/PGE2 pathway in response to IH, both 
cell types (macrophages and LLC1 cells) are relevant sources of PGE2 in our murine model of OSA.
In conclusion, the increased tumor malignant properties associated with IH appear to be mediated, at least in 
part, by the up-regulation of the COX-2/PGE2 pathway in tumor cells and macrophages. Our findings provide 
further support to the concept that NSAIDS, and more concretely Ce, could provide effective benefits in the treat-
ment of tumors whose proliferative properties and vascularity patterning make them more susceptible to regional 
hypoxic cycles, as well as in the context of cancer patients suffering from OSA.
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